Packard BioSience erhält Patent - 500 Beiträge pro Seite

[Ronny-D]

Packard BioScience Receives Patent for Computer-Controlled Biochip Production Technology
- Growing Intellectual Property Base Covers Pioneering Technologies for Automating Biochip Production -

MERIDEN, Conn., Aug. 8 /PRNewswire/ --
Packard BioScience Company (Nasdaq: PBSC - news) announced today that it has been awarded U.S. Patent and Trademark Office patent number 6,094,966, entitled, ``Method for Verifying Proper Operation of a Liquid Sample Dispenser.`` The patent covers methods for using Packard`s pioneering piezo-electric dispensing technology with its computer-controlled robotic liquid handling systems to deliver minute droplets which enable the production of inexpensive, high-quality biochips and microarrays. With this patent, Packard further enhances its intellectual property position in automated biochip production techniques using non-contact, drop-on-demand liquid transfer and printing.

The implementation of this technology on computer-controlled robotic workstations significantly enhances Packard`s ability to offer a biochip fabrication approach that is scaleable, cost-effective, and easily transferable to multiple production sites. Non-contact, drop-on-demand printing of biochips and microarrays offers drug discovery and genomics researchers unprecedented flexibility, particularly with respect to spot density and substrate choice. In addition, this technology is suitable for diverse applications, including gene-chips for genotyping and gene expression analysis, and protein chips for functional proteomic studies and drug discovery.

``We believe Packard`s drop-on-demand biochip printing technology is the most cost-effective, reproducible method for fabricating high-quality microarrays for a wide range of genomics and proteomics applications,`` said Emery Olcott, Chairman and Chief Executive Officer of Packard BioScience. ``Biochip production systems are increasingly becoming a la carte and Packard`s automated production techniques are well suited for the production of customized biochips.``

Packard has a growing intellectual property portfolio in biochips. Last month, Packard announced the receipt of U.S. patents 6,079,283 and 6,083,762, which together include 44 claims providing broad and fundamental coverage encompassing biochip production by transfer of liquids through non-contact dispensing. Prior to those patents, Packard had been issued U.S. patent 5,927,547, entitled, ``System for Dispensing Microvolume Quantities of Liquids,`` in July of 1999. This patent included 14 claims, providing broad coverage of very small volume liquid dispensing. The Company has also received notice of allowance for three additional patent applications relating to the use of computer-controlled robotics for drop-on-demand dispensing.

Biochips containing microarrays of genetic information promise to be one of the most important research tools in the post-genome era. They are one of the few platforms that can carry out the highly parallel analysis needed to exploit the explosive growth in genetic information resulting from the sequencing of the human genome. Initial applications will be in drug discovery, pharmacology and clinical research. The emerging field of pharmacogenomics is especially expected to benefit from biochip analysis, eventually leading to mass diagnostic and personalized medicine applications. Other biochip applications will include forensics, toxicology and epidemiological research.

Packard BioScience Company is a leading global developer, manufacturer and marketer of instruments and related consumables and services for use in the life sciences research and nuclear industries. The Company is primarily focused on the rapidly growing areas of drug discovery, genomics and biochip analysis and is continuing to develop integrated platforms based on a wide range of technologies and instrumentation. These platforms are designed to support the industrialization of drug discovery by bringing the benefits of miniaturization, automation and ultra-high throughput analysis to these areas. Packard`s experience in working in more than 60 countries with market leading customers has allowed the Company to establish a worldwide leadership position in many of its primary product categories, with well-recognized brand names and a reputation for high quality, reliable instruments.

Certain statements contained herein are ``forward looking`` statements which involve a high degree of risk and uncertainty, including, without limitation, the prospective statements regarding the expected expansion of biochip applications and the Company`s ability to capitalize on such expansion. Many factors could cause actual results to differ materially from these statements including, without limitation, loss of market share from competition, the ability to successfully introduce new products and platforms, market acceptance of new products and platforms, the ability to protect the Company`s intellectual property, not infringing on the intellectual property rights of others, changes in the markets the Company serves and economic issues such as interest rate and foreign exchange fluctuations. These and other risk factors are discussed in detail in the Company`s filings with the Securities and Exchange Commission.

[trollus]

Eine weitere Patentzulassung bei Collateral Ther./CLTX/915303
-u.s. patent for angiogenic - gene therapy-

08.08.00 Hochstufung durch "Prudential" -Strong Buy-
(gen.Kursziel $ 90)

nachl. bei www.netinvestor.com unter up-and downgr.